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Purpose: Traditionally, oral estrogens have been used for hormone replacement therapy. 
However, in Japan, additional estrogen formulations have been used, including transdermal 
patches and transdermal gels. The latter have a unique commonality with cosmetics because 
both of them are applied to the skin. Beauty care is one of the most important lifestyle factors 
for women, and it has been reported that the amount of attention paid to beauty care has an 
effect in determining whether or not women will choose to undergo HRT during menopause. 
Therefore, our study focused on estrogen formulations and beauty care practices.
Patients and methods: Fifty women who use hormone replacement therapy were recruited 
from the outpatient clinic of Tohoku University Hospital. They were treated with oral conjugated 
estrogen (n = 11), transdermal 17β-estradiol patch (n = 11), and transdermal 17β-estradiol gel 
(n = 28). They completed a questionnaire to assess their lifestyle (beauty care practices and 
exercise habits) and their compliance. The transdermal gel users were further interviewed about 
their subjective impressions regarding “smell”, “sticky feeling”, “spreadability”, and “irritation” 
on the skin using a five-grade scale.
Results: There were no differences in the usability of medicines and patient compliance among 
the estrogen formulations. We observed a positive tendency between the level of beauty care and 
transdermal gel use (P = 0.0645, ordinary logistic regression analysis). The gel users placed top 
priority on a lack of “sticky feeling” but the subjective impression regarding “sticky feeling” was 
worst among the four factors (P , 0.01, Steel–Dwass test). Correspondence analysis showed that the 
subjective impressions of transdermal gel corresponding to usability in the range of “moderate” to 
“very good” and “sticky feeling” greatly affected the usability of the formulation.
Conclusion: These results suggest that the level of attention to beauty care plays some role in 
the choice of estrogen formulations.
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Introduction
Hormone replacement therapy (HRT) has been widely used for the control of   vasomotor 
symptoms of post- and perimenopausal women.1,2 HRT is also employed for the 
treatment of premature ovarian failure (POF).3 Women with untreated   premature 
ovarian failure are at increased risk of osteoporosis, cardiovascular disease, and 
dementia, among others. The common types of estrogen for estrogen therapy are 
conjugated equine estrogen and 17-β-estradiol. There are no data to suggest that any 
one formulation is clinically superior to another.4 Traditionally, oral estrogens have 
been used for estrogen therapy, but they have several disadvantages such as variable 
bioavailability and hepatic first-pass metabolism. To circumvent the side effects of 
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the oral route, approaches using the transdermal route have 
been developed.5 Transdermal formulations, such as trans-
dermal patches and transdermal gels, are available in Japan. 
Transdermal gels have a unique commonality with cosmetics 
because both of them are applied on the skin.
Beauty care is one of the most important lifestyle 
factors for women. It has been previously reported that 
the amount of attention paid to beauty care plays a role 
in determining HRT during menopause.6 Women tend to 
expect anti-aging effects such as maintaining a youthful 
appearance,   improving skin tone, and preventing wrinkles 
to accompany HRT use.7 However, there have been no 
reports about the type of estrogen formulations and beauty 
care practices. In this study, we have investigated the 
relationship between estrogen formulations and beauty 
care practices and studied the usability of transdermal gel 
according to its cosmetic aspects.
Material and methods
The study was carried out in accordance with the principles 
outlined in the Declaration of Helsinki.8 Our institutional 
review board at Tohoku University approved the study 
(2010-390).
Study population
A cross-sectional study was conducted from November to 
December 2010. Fifty women, aged 22–58 years, who use 
HRT were recruited from the gynecologic outpatient clinic 
of Tohoku University Hospital in Sendai, Japan. They were 
all diagnosed with loss of ovarian function. They provided 
informed consent and could complete a questionnaire by 
themselves. They had used the same type of estrogen formula 
for at least 2 months.
Questionnaire
The questionnaire consisted of four parts. The first part 
included general profile factors such as age, occupation, time 
from the initiation of treatment to screening, type of estrogen 
(oral tablet, transdermal patch, or transdermal gel), and medi-
cal application. According participants’ answers to this part, 
we divided the subjects into three groups: group 1, oral-con-
jugated estrogen (Premarin®; Pfizer, Tokyo, Japan) 0.625 mg/
day (n = 11), group 2, transdermal 17β-estradiol patch 
(Estrana®; Hisamitsu, Tokyo, Japan) 0.72 mg/2 days (n = 11), 
and group 3, transdermal 17β-estradiol gel (  Devigel®; Motida, 
Tokyo, Japan) 1 mg/day (n = 28). The second part addressed 
usability and compliance. We asked, “What is the usability 
of your estrogen formula?” with the possible responses   
of “favorable”, “rather favorable”, “neutral”, “rather 
  unfavorable”, or “unfavorable”. We also asked, “How often 
do you forget your medication per month?” with the pos-
sible responses of “never”, “once”, “twice”, “three times”, 
or “more than three times”. The third part included questions 
about lifestyle (beauty care practices and exercise habits) with 
four grades. As to the beauty care practices, we asked, “How 
often do you put on makeup?” with the possible responses 
of “every day”, “sometimes”, “rarely”, or “never”. As to 
their exercise habits, we asked, “How often do you engage 
in mild exercise?” with the possible responses of “once a 
week”, “once a month”, “once per 3 months”, or “never”. 
The transdermal gel users were further interviewed in the 
fourth part of the questionnaire. We asked about their prior-
ity regarding “smell”, “sticky feeling”, “spreadability”, and 
“irritation” on the skin using a four-grade scale. Subjective 
impressions regarding these factors were also gathered using 
a five-grade scale.
Analysis
The significance of differences was evaluated by Chi-square 
test, Kruskal–Wallis test, or Steel–Dwass test. Statistical 
analysis was performed using Excel (2010; Microsoft Cor-
poration, Redmond, WA) with the add-in software Statcel 3 
(OMS, Tokyo, Japan), and SAS (v 9.1.3; SAS Institute Inc, 
NC, US). Statistical significance was set at P , 0.05.
Results
General profile
We began by analyzing the questionnaire results for 
part 1. Demographic and clinical characteristics are shown 
in Table 1. The tablet group was younger than the gel group 
(P , 0.05). There were no differences between the groups 
with regards to occupation, time from the initiation of treat-
ment, and medical application (P . 0.05).
Usability and compliance
The questionnaire results for part 2 are shown in Table 2. 
There were no differences between the groups with regard 
to usability and compliance (P . 0.05).
Beauty care practices and exercise habits
Next we analyzed the questionnaire results for part 3 
(Table 3). There were no differences between the groups 
with regard to beauty care practices and exercise habits 
(P . 0.05). We further divided the subjects into three 
groups according to the frequency of beauty care practices 
and exercise habits (Figure 1). There were no differences 
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between the groups with regard to age. According to the 
ordinary logistic regression analysis, we could detect a posi-
tive tendency, although it was not statistically significant, 
between the level of beauty care practices and transdermal 
gel use (P = 0.0645).
Priority and usability for transdermal  
gel users
We further analyzed the questionnaire results for part 4 
(  Figure 2). Transdermal gel users gave the highest priorities 
for lack of “sticky feeling” and lack of “irritation”. As to 
the subjective impression of gel usability, “sticky feeling” 
had the lowest rating.
Correspondence analysis of the 
subjective impression and the usability  
of transdermal gel
Next we analyzed the relationship between the   subjective 
  impression of gel usability and the usability of gel. 
  Correspondence analysis graphically showed that the 
  subjective impressions of transdermal gel corresponding 
to usability in the range of “moderate” to “very good” 
and “sticky feeling” greatly affected the usability of the 
  formulations (Figure 3).
Discussion
This is the first report about the relationship between 
  estrogen   formulations and beauty care practices; we also 
studied the usability of the transdermal gel according to its 
cosmetic aspects.
Transdermal  estrogen  administration  bypasses 
  first-pass metabolism and offers some advantages over 
oral   administration.5 In view of these advantages, we rec-
ommend the administration of transdermal formulations 
(patch or gel) for all HRT users in our clinic. This would 
explain the high percentage of transdermal   administration. 
However, there are some disadvantages, such as skin 
Table 1 Demographic and clinical characteristics
Group 1  
(tablet)  
n = 11
Group 2  
(patch)  
n = 11
Group 3  
(gel)  
n = 28
Age (years) mean (SE) 34.5 (3.34)* 44.2 (2.45) 43.1 (1.63)
Occupation
  Business worker 6 2 7
  Individual proprietor 0 0 1
  Part-time worker 2 5 6
  Housewife 1 3 12
  Unemployed 1 1 2
  Others 1 0 0
P = 0.263 (by Chi-square test)
Time from initiation  
of treatment (months)
 , 3 1 2 5
  3–6 2 3 6
  6–12 2 0 8
 . 12 6 6 9
P = 0.499 (by Chi-square test)
Medical application
  Climacteric disorder 1 2 12
    Surgically or drug-induced  
menopause
4 4 8
  Premature ovarian failure 6 5 8
P = 0.240 (by Chi-square test)
Note: *P , 0.05 vs gel (by one-way ANOVA followed by Scheffe’s F-test).
Table 2 Usability and compliance
Group 1  
(tablet)  
n = 11
Group 2  
(patch)  
n = 11
Group 3   
(gel)  
n = 28
Usability: “What is the usability  
of your estrogen formula?”
  “Favorable” 2 5 4
  “rather favorable” 3 2 11
  “Neutral” 6 4 10
  “rather unfavorable” 0 0 3
  “Unfavorable” 0 0 0
P = 0.312 (by Kruskal–Wallis test)
Compliance: “How often do  
you forget your medication  
per month?”
  “Never” 5 8 13
  “Once” 4 1 8
  “Twice” 1 1 4
  “Three times” 0 0 3
  “More than three times” 1 1 0
P = 0.478 (by Kruskal–Wallis test)
Table 3 Beauty care practices and exercise habits
Group 1  
(tablet)  
n = 11
Group 2  
(patch)  
n = 11
Group 3   
(gel)  
n = 28
Beauty care practices: “How often  
do you put on makeup?”
  “Every day” 4 3 18
  “Sometimes” 4 0 7
  “rarely” 1 0 1
  “Never” 2 2 2
P = 0.253 (by Kruskal–Wallis test)
Exercise habits: “How often do you  
engage in mild exercise?”
  “Once a week” 4 4 16
  “Once a month” 0 2 1
  “Once per three months” 0 0 0
  “Never” 7 5 11
P = 0.394 (by Kruskal–Wallis test)
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Tablet
Patch
Gel
Group 3 Group 2 Group 1
Group
3
Group
2
Group
 1
Beauty care
practices
Beauty care practices
High: “every day”, “sometimes”
High: “once a week”, “once a month”
Low: “rarely”, “never”
Low: “once per three months”, “never”
Sports habits Sports habits
High High
High
41.4
(1.65)
42.8
(2.43)
38.5
(4.42)
Low
Low-
high
Low
Age (years)
mean (SE)
P = 0.585
(by one-way
ANOVA)
(n = 23)
10
20
30
40
50
60
70
80
90
100 (%)
(n = 19) (n = 8)
25.0
37.5
26.3
69.6
17.4
13.0
47.4
Figure 1 relationship between the level of beauty care and choice of estrogen formulations.
Note: P = 0.0645, ordinary logistic regression analysis.
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Priority
Subjective impression
Smell Sticky feeling Spreadability Irritancy
Smell
0
1
2
3
4
5
0
1
2
3
4
5
6
Sticky feeling Spreadability Irritancy
Figure 2 Estimate of priority and subjective impression in transdermal gel users. Priority (A) and subjective impression (B) in transdermal gel users were assessed as 
described in the “Materials and methods” section.
Notes: *P , 0.05; **P , 0.01 (Steel–Dwass test).
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  irritation and poor adhesion.9 The biggest disadvantage is 
that   transdermal administration is bothersome because of its 
unfamiliar mode of administration. Most drugs are admin-
istered orally and the transdermal route is only used in a 
minority. Our data showed that there were no differences in 
the usability and compliance of medicines among the estro-
gen formulations, so the bothersome handling of transdermal 
administration did not seem to be a burden to HRT users. In 
general, women are more familiar with beauty care practices 
than men and our data showed that only 16% of HRT users 
had a low-frequency makeup habit. It is   possible that most 
of the women could handle the transdermal formulas easily, 
given their similarity to cosmetics.
It has been previously reported that HRT use and the 
level of beauty care practices were positively associated.6 
Women might expect anti-aging effects such as maintain-
ing a youthful appearance and skin tone from HRT use. 
Because of its unique commonality with cosmetics, we 
expected that transdermal gel users might show high levels 
of beauty care practices. Contrary to our expectation, we 
could not detect a difference in beauty care practice levels 
between those using different estrogen formulas (Table 3). 
More than half of the women reported that they practice 
beauty care every day, so we speculated that we could not 
detect a difference because of their strong preference for 
makeup. We further divided the high-frequency beauty 
care practice group into two groups according to exercise 
habits (Figure 1). Exercise habits might reflect a positive 
mental attitude and women might expect anti-aging effects 
from exercise such as maintaining a youthful body and a 
good shape. Group 1 (high in beauty care practices, high 
in exercise habits) seemed to be more active than Group 2 
(high in beauty care practices, low in exercise habits) in 
terms of their beauty care practices. 
Possible avenues for future research include more 
detailed questions about beauty care practices such as usage 
of antiwrinkle cream, facial treatment, and cosmetic surgery 
might be useful to deepen our understanding of this issue. 
Concerning the compliance of patients using the different 
formulas, it would also be interesting to measure the plasma 
levels of estradiol with the use of the different formulas.
Our data suggested that “sticky feeling” is the biggest 
challenge for the transdermal gel formula. In Japan, we can 
use only one type of transdermal 17β-estradiol gel under the 
national health insurance system. Two newer types of transder-
mal estrogen formulas, transdermal spray and topical emulsion, 
are clear and not sticky.10,11 Introduction of these formulas to 
Japan would potentiate the usage of transdermal estrogen.
Conclusion
Our data suggested that the level of attention to beauty care 
plays some role in the choice of estrogen formulation. Trans-
dermal gel formula was acceptable in view of the cosmetic 
aspects. “Sticky feeling” is the biggest challenge for the 
transdermal gel formula.
Disclosure
The authors report no conflicts of interest in this work.
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Figure 3 Correspondence analysis of the subjective impression and the usability of transdermal gel.
Notes: • (closed circle): subjective impression; ♦ (closed diamond): usability.
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